|
Affiliation |
Hospital Internal MedicineⅢ |
Graduating School 【 display / non-display 】
-
2003.04-2009.03
Akita University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-2018.09
Akita University Graduate School, Division of Medicine Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2024.04-Now
Akita University Hospital Internal MedicineⅢ Lecturer
-
2022.04-2024.03
Akita University Hospital Internal MedicineⅢ Assistant Professor
-
2020.10-2022.03
Akita University Hospital Central Laboratory Division Assistant Professor
Research Areas 【 display / non-display 】
-
Life Science / Hematology and medical oncology
-
Life Science / Hematology and medical oncology / 血液腫瘍内科
Thesis for a degree 【 display / non-display 】
-
Phase II clinical trial of lenalidomide and dexamethasone therapy in Japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide
小林 敬宏
Therapeutic Drug Monitoring 2018.09 [Refereed]
Domestic Co-author
Research Achievements 【 display / non-display 】
-
Successful cord blood transplantation for refractory gamma-delta hepatosplenic T-cell lymphoma developed during treatment of Crohn's disease
SAITO Akihito, NARA Miho, FUJISHIMA Takashi, KUROKI Wataru, YAMASHITA Takaya, KOBAYASHI Takahiro, IKEDA Sho, KITADATE Akihiro, KAMEOKA Yoshihiro, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 65 ( 1 ) 41 - 46 2024
Research paper (journal)
<p>The patient was a 21-year-old man who had been diagnosed with Crohn's disease and received infliximab and azathioprine six years earlier. He was admitted with fever and fatigue. Peripheral blood examination showed LDH 2,473 U/<i>l</i> and thrombocytopenia, and contrast-enhanced computed tomography (CT) showed hepatosplenomegaly. Bone marrow biopsy and liver biopsy showed CD4+CD56+TCR<i>γδ</i>+CD8<sup>−</sup> atypical cells, leading to a diagnosis of hepatosplenic T-cell lymphoma (HSTCL). The patient was refractory to CHOP and DA-EPOCH, and therefore received cord blood transplantation with myeloablative conditioning. CT showed reduced in hepatosplenomegaly and peripheral blood examination showed LDH 165 U/<i>l</i> and plt 180,000/µ<i>l</i>, so the patient was discharged on day117. HSTCL is a tumor of immature <i>γδ</i>T cells with a V<i>δ</i>1 mutation in the spleen, and immunodeficiency has been implicated in its pathogenesis. Patients with inflammatory bowel disease treated with azathioprine are known to have an increased risk of lymphoproliferative disease. In this case, use of immunosuppressive drugs for Crohn's disease may have caused malignant transformation of <i>γδ</i> cells in the intestinal epithelium. Although the patient was refractory to chemotherapy, he was able to achieve remission with early cord blood transplantation and long-term survival is expected.</p>
-
Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single-Center Cohort Study.
Nagi Tozawa, Takaya Yamashita, Miho Nara, Yuki Fujioka, Sho Ikeda, Takahiro Kobayashi, Isuzu Kobayashi, Akihiro Kitadate, Yoshihiro Kameoka, Naoto Takahashi
Cureus 15 ( 12 ) e50416 2023.12
Research paper (journal)
Introduction The overall survival (OS) of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) has improved with the combination of tyrosine kinase inhibitor (TKI) with intensive chemotherapy. In recent years, there has been increased interest in the possibility of long-term survival without allogeneic hematopoietic stem cell transplantation (HSCT) or maintenance therapy. The aim of this study was to determine the effectiveness of treatment and the resultant outcomes in Ph+ALL patients using real-world data. Methods We performed a single-center retrospective analysis utilizing Akita University Hospital data (Akita, Japan) from November 2000 to June 2023 to evaluate the outcomes of TKI with intensive chemotherapy for Ph+ALL. Results Twenty-three patients with Ph+ALL were treated with intensive chemotherapy combined with TKI, including six imatinib, four dasatinib, and 13 ponatinib. The median patient age was 53 years (range; 28-67). Eighteen patients (78%) achieved complete molecular remission (CMR) within three months. HSCT was performed in 16 patients (70%), all of whom did not receive post-transplant TKI maintenance therapy. Six of the seven patients who did not undergo HSCT received maintenance therapy with ponatinib after intensive chemotherapy. The three-year OS was 81%. Ponatinib treatment resulted in a much higher OS rate than imatinib/dasatinib (100% vs. 60%; P=0.011). CMR within three months was identified as a prognostic factor for molecular relapse-free survival (hazard ratio (HR)=0.22; P=0.027). CD20 positivity was identified as a risk factor for hematological relapse (HR=5.2, P=0.032). Conclusion Even in a single-center cohort study, ponatinib, as a combination TKI with intensive chemotherapy or maintenance therapy, may improve the prognosis of Ph+ALL. Patients with CMR within three months might not necessarily need to receive HSCT, but a subsequent treatment-free status could have been achieved only by HSCT. Furthermore, CD20 positivity may be a useful biomarker for future treatment decisions in patients with Ph+ALL.
-
Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto
Cancer Chemotherapy and Pharmacology ( Springer Nature ) 2024
-
AMLのVEN/AZA治療におけるベネトクラクスの血中濃度と好中球減少症との関連
小林 敬宏, 佐藤 保奈実, 三浦 昌朋, 福司 弥生, 藤田 菜々子, 黒木 航, 伊藤 史子, 手島 和暁, 渡部 敦, 藤島 直仁, 高橋 直人
日本血液学会学術集会 ( (一社)日本血液学会 ) 85回 377 - 377 2023.10
-
髄外病変はヒアルロン酸とCD44バリアントを介した骨髄腫細胞同士の凝集から発症する(Extramedullary diseases originate from hyaluronan-induced homophilic cell-cell interaction of CD44 variant-expressing myeloma cells)
菊池 次郎, 小玉 信之, 竹下 昌孝, 比島 智子, 池田 翔, 小林 敬宏, 黒田 芳明, 内山 倫宏, 長田 直希, ボーゲン・ビヤーネ, 安井 寛, 高橋 直人, 三輪 哲義, 古川 雄祐
International Journal of Myeloma ( (一社)日本骨髄腫学会 ) 12 ( 3 ) 111 - 111 2022.05
-
KUROKI Wataru, KOBAYASHI Takahiro, UMAKOSHI Michinobu, KITADATE Akihiro, IMAIZUMI Chihiro, SAITO Masaya, KOBAYASHI Isuzu, FUJISHIMA Masumi, FUJISHIMA Naohito, YOSHIOKA Tomoko, GOTO Akiteru, TAKAHASHI Naoto
Rinsho Ketsueki ( The Japanese Society of Hematology ) 63 ( 6 ) 523 - 529 2022
<p>Atraumatic splenic rupture (ASR) is a rare but fatal complication of malignant lymphoma. However, only one case of intravascular large B-cell lymphoma (IVLBCL)-related ASR (IVLBCL-ASR) has previously been reported, and the mechanism of IVLBCL-ASR is unknown. We present the case of a 78-year-old man who died unexpectedly and was diagnosed with IVLBCL-ASR pathologically by autopsy. A massive intraperitoneal hemorrhage and four lacerations on the splenic surface were discovered during the autopsy. CD20-positive lymphoma cells that infiltrated into small vessels were highly concentrated in the center of the spleen and were only slightly distributed in the lacerations on the splenic surface. Therefore, increased intrasplenic pressure due to lymphoma cell proliferation was identified as the cause of ASR. The patient had undergone <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT) for tongue cancer evaluation 3 months earlier, and positive uptake was found in the right adrenal gland, where lymphoma cell infiltration was confirmed by the autopsy. Our findings suggest that clinicians should be aware that the advanced stage of IVLBCL can cause fatal ASR via increased intrasplenic pressure. Therefore, early diagnosis and early treatment intervention are desirable to prevent the onset of IVLBCL-ASR, and <sup>18</sup>F-FDG PET/CT is useful for the early diagnosis of IVLBCL.</p>
-
髄外疾患はヒアルロナン誘導同種親和性骨髄腫細胞-細胞相互作用に由来する【JST・京大機械翻訳】|||
菊池次郎, 小玉信之, 小玉信之, 竹下昌孝, 竹下昌孝, 比島智子, 比島智子, 池田翔, 小林敬宏, 黒田芳明, 内山倫宏, 長田直希, 小山大輔, BOGEN Bjarne, 安井寛, 高橋直人, 三輪哲義, 三輪哲義
日本血液学会学術集会抄録(Web) ( (一社)日本血液学会 ) 83rd ( 2 ) OS2 - 1 2021
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Early-Career Scientists
Project Year： 2020.04 - 2023.03
-
Grant-in-Aid for Early-Career Scientists
Project Year： 2020.04 - 2023.03